The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...

Key Takeaways Novo Nordisk cut Wegovy’s price to $499 per month, a 23% decreaseEli Lilly lowered Zepbound’s starter dose to ...

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...

The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Hims & Hers Health ( HIMS -12.56%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...